This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Shire Management Discusses Q2 2012 Results - Earnings Call Transcript

Shire (SHPG)

Q2 2012 Earnings Call

August 01, 2012 9:00 am ET


Eric Rojas - Director of Investor Relations - North America

Angus C. Russell - Chief Executive Officer, Interim President of Specialty Pharma and Executive Director

Graham Hetherington - Chief Financial Officer, Principal Accounting Officer and Director

Sylvie L. Gregoire - President of Human Genetic Therapies Business and Member of Management Committee

Kevin L. Rakin - Chief Executive Officer of Advanced Biohealing and President of Regenerative Medicine


Ken Cacciatore - Cowen and Company, LLC, Research Division

Peter Verdult - Morgan Stanley, Research Division

William Tanner - Lazard Capital Markets LLC, Research Division

Brian Bourdot - Barclays Capital, Research Division

Jo Walton - Crédit Suisse AG, Research Division

Frank H. Pinkerton - SunTrust Robinson Humphrey, Inc., Research Division

David G. Buck - The Buckingham Research Group Incorporated

David Amsellem - Piper Jaffray Companies, Research Division



Hello, and welcome to Shire's 2012 Second Quarter Results Call. [Operator Instructions] Just to remind you, this conference call is being recorded. Today, I'm pleased to present Eric Rojas. Please begin your call.

Eric Rojas

Good morning and good afternoon, everyone. Thank you for joining us today for Shire's Second Quarter 2012 Financial Results. By now, you should have all received our press release and should be viewing our presentation via our website on If for some reason you have not received the press release or are unable to access our website, please contact Souheil Salah in our U.K. Investor Relations department on +44-1256-894-160, as he will be happy to assist you.

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs